Saving Face? Cell Therapeutics Withdraws Pixantrone NDA Ahead Of Advisory Committee Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Company’s announcement that it pulled the NDA for its investigational non-Hodgkin’s lymphoma treatment comes after the sponsor would have received FDA’s background briefing document for the Feb. 9 Oncologic Drugs Advisory Committee meeting.
You may also be interested in...
Array Withdraws Binimetinib's US Filing On Heels Of Late-Cycle Meeting With FDA
Company explored ‘a number of paths to approval’ with agency, but modest progression-free survival benefit in monotherapy treatment of NRAS-mutant melanoma appears to have doomed the new drug application, which was pulled less than two weeks before advisory committee review.
Biosimilar Bummer: FDA Postpones Celltrion Infliximab Advisory Committee
Pending information requests lead to delay of the March 17 meeting.
Cell Therapeutics’ Tosedostat Gets Back On Track
FDA lifts clinical hold on first-in-class aminopeptidase inhibitor tosedostat, in investigator-sponsored Phase II trials for blood-related cancers as part of the company’s economic development strategy.